Every pharmaceutical distributor in India operates under Good Distribution Practice (GDP) rules set by the Central Drugs Standard Control Organisation (CDSCO) and enforced during Form 20/21 licence renewal and unannounced inspections. The single largest risk point is not maintaining temperature. It is failing to prove you maintained temperature when challenged.
Inspectors do not ask about your SOP; they ask for your data logger printout, your excursion log, and evidence of corrective action. This playbook walks you through the documentation architecture, the mechanics of a batch recall, and the 12-point self-audit cycle that keeps your licence intact.
Advisory
CDSCO inspection teams under Schedule M (Part II) rules verify cold-chain integrity via continuous temperature recording devices (data loggers) installed in refrigerated storage units and transport vehicles. A digital or paper log showing temperature readings at minimum 4-hourly intervals is the baseline; many inspectors now expect sub-hourly intervals (every 15–30 minutes) for critical-phase storage (2–8°C for biologics and vaccines). If your log shows a 2-hour gap or a reading above 8°C with no corresponding entry in an Excursion Register (Form maintained separately, with root cause and CAPA—Corrective and Preventive Action—recorded within 24 hours), the inspector will flag the batch as non-compliant and may initiate a recall. Document proof of calibration of every logger (monthly minimum; calibration certificate valid for 12 months under ISO 9001 standards used in pharma labs) and maintain a signed handover log when transferring goods between storage or vehicles—this breaks the chain and is the second most-cited deficiency.
An excursion is any deviation from the specified temperature range for a medicine or vaccine. Under Schedule M Part II, once an excursion is detected (usually when staff review the data logger output), you must log it in an Excursion Register within 24 hours, classify it (minor: <2°C above range for <2 hours; major: ≥2°C above range or any time in range-critical phase), and decide: discard, quarantine pending stability data, or release with enhanced monitoring. A minor excursion in a non-sensitive formulation (e.g., tablets stored at 25±2°C that sat at 27°C for 90 minutes) typically allows release after CAPA (e.g., repair refrigerator compressor, retrain staff on temperature checks). A major excursion in a vaccine or biologic almost always triggers quarantine and request for stability data from the manufacturer or third-party lab (₹15,000–₹50,000 per batch, 7–14 days turnaround). If you cannot prove stability, the batch is destroyed. Inspectors verify that your CAPA is documented, dated, and assigned to a named person (e.g., 'Plant Head to inspect compressor seals by 26 July 2026') with closure evidence attached (receipt from technician, new calibration cert). Absence of CAPA or closure evidence within the stated deadline is a major deficiency.
A recall is classified as Class I (risk of serious harm or death), Class II (risk of adverse health effect or mild harm), or Class III (no health risk but violates regulations—e.g., expired labels or batch code mismatch). Under Schedule M Part II and the Pharmacovigilance Programme for Adverse Drug Reactions (notified by CDSCO), you must initiate a recall within 48 hours of identifying the defect (e.g., contamination, stability failure, labelling error
Frequently asked questions
CDSCO requires minimum 4-hourly intervals; inspectors increasingly expect sub-hourly intervals (15–30 minutes) for critical-phase storage at 2–8°C for biologics and vaccines under Schedule M (Part II) rules.
You must log it in a separate Excursion Register within 24 hours with root cause and CAPA documented. Failure to do so will flag the batch as non-compliant and may trigger a recall.
Data loggers must be calibrated monthly minimum, with calibration certificates valid for 12 months under ISO 9001 standards used in pharmaceutical labs.